What Is the Best Pain Medication for Rheumatoid Arthritis?

There is no single best pain medication for rheumatoid arthritis because the pain itself comes from more than one source and the right drug depends on your disease stage, your other health conditions, and how your body responds. For most people, the foundation of pain control is a disease-modifying drug like methotrexate that slows joint destruction and quiets the inflammation driving most of the pain. On top of that, anti-inflammatory painkillers, corticosteroids, and newer targeted therapies each play a role at different moments. The answer gets more interesting when you learn that roughly a third of people with RA still have significant pain even after inflammation is well controlled, which changes the medication strategy entirely.

Why Controlling Inflammation Is the Real Pain Strategy

Rheumatoid arthritis pain is overwhelmingly driven by the immune system attacking joint tissue. That means the most effective long-term pain relief comes not from traditional painkillers but from drugs that suppress that immune attack. Methotrexate, the most widely used disease-modifying antirheumatic drug (DMARD), remains the first treatment most rheumatologists reach for. In a five-year prospective study, about 70% of patients on methotrexate showed marked improvement in both joint pain and swelling.¹ That kind of sustained benefit makes methotrexate less of a “painkiller” in the traditional sense and more of a disease controller that happens to reduce pain by addressing its root cause.

This distinction matters practically. If you think of pain management in RA as reaching for a pill when something hurts, you will end up chasing symptoms while the disease eats away at your joints. The modern approach flips this: get disease activity under control first, then layer on pain-specific medications for whatever discomfort remains. Everything discussed below sits on top of that foundation.

NSAIDs and How to Choose Between Them

Nonsteroidal anti-inflammatory drugs like ibuprofen, naproxen, and celecoxib are the workhorses for day-to-day RA pain. They reduce both inflammation and pain, and most people with RA will use one at some point. The question people ask most often is which NSAID is safest, and the answer has shifted over the years.

Celecoxib (a COX-2 selective NSAID) was once viewed with suspicion after a related drug, rofecoxib, was pulled from the market for heart risks. A large trial of over 24,000 arthritis patients comparing celecoxib head-to-head with ibuprofen and naproxen found that celecoxib was no worse for cardiovascular events than either of the older drugs. Cardiovascular events occurred in about 2.3% of the celecoxib group versus 2.5% for naproxen and 2.7% for ibuprofen. Celecoxib caused fewer gastrointestinal problems than both naproxen and ibuprofen, and fewer kidney events than ibuprofen.² A Cochrane review confirmed the stomach advantage: people on celecoxib had far fewer gastric ulcers than those on traditional NSAIDs, with roughly 4% developing ulcers compared to about 17% on older NSAIDs.³

That said, no NSAID is risk-free. If you have existing heart disease or multiple cardiovascular risk factors, even moderate NSAID use raises your chances of a cardiovascular event. One systematic review found that patients with existing cardiovascular disease had roughly a threefold increased likelihood of a further event while on NSAIDs.⁴ For kidney health, a long-term cohort study of RA patients found that NSAIDs did not accelerate kidney decline in people with normal or mildly reduced kidney function, but they did speed up decline in those who already had advanced kidney impairment.⁵ So the practical advice is: if your heart and kidneys are in good shape, NSAIDs are a reasonable ongoing option. If they are not, your doctor will likely steer you toward other approaches.

Protecting Your Stomach While Taking NSAIDs

If you take an NSAID regularly, your doctor may pair it with a proton-pump inhibitor (PPI) like omeprazole to reduce the risk of ulcers and stomach bleeding. This combination is included in many prescribing guidelines and is generally regarded as safe.⁶ A cost-effectiveness analysis found that for average-risk patients, adding a separate PPI to your NSAID was the most cost-effective gastroprotective strategy, though compliance matters: the protection only works if you actually take the PPI consistently.⁷ People at higher risk of stomach problems, such as those over 65, those with a history of ulcers, or those also taking corticosteroids, benefit the most from this pairing.

Corticosteroids for Flares

When RA flares, the pain can escalate quickly enough that waiting for a DMARD adjustment to take effect is not practical. Low-dose oral corticosteroids like prednisolone, kept at or below 15 mg per day, can bring rapid relief. A Cochrane review found prednisolone to be highly effective for short-term use during flares, though it comes with real risks including fractures and infections with prolonged use.⁸

For pain concentrated in one or two joints, steroid injections directly into the affected joint can be remarkably fast-acting. In a prospective study of RA patients receiving finger joint injections, about three-quarters reported pain scores of 2 or less (on a 0–10 scale) within two weeks, with most reaching that level by day four.⁹ Another study using triamcinolone acetonide injections showed significant reductions in pain, swelling, and morning stiffness that lasted through 12 weeks with no major safety concerns.¹⁰ The catch is that repeated injections into the same joint can damage cartilage over time, so most rheumatologists limit frequency.

JAK Inhibitors and Their Unusual Pain Benefits

Among the newer classes of RA medications, Janus kinase (JAK) inhibitors have drawn particular attention for pain relief. Drugs like tofacitinib, baricitinib, and upadacitinib work by blocking specific signaling pathways inside immune cells. What makes them interesting from a pain perspective is that they seem to reduce pain faster and to a somewhat greater degree than older biologics.

A Swedish nationwide cohort study found that patients starting a JAK inhibitor experienced a greater decrease in pain at three months compared to those starting a TNF inhibitor, with similar advantages over other biologic DMARDs.¹¹ Real-world data showed that after 24 weeks on a JAK inhibitor, about half of patients achieved at least a 50% improvement in pain, and roughly a third achieved 70% improvement.¹² Evidence from clinical trials also suggests improvements in patient-reported pain scores tend to emerge within one to two weeks, which is faster than what most biologic DMARDs deliver.¹³

This speed may partly reflect that JAK inhibitors appear to act on pain pathways beyond just inflammation, though the evidence on that mechanism is still developing. For patients who have tried a biologic DMARD and still have bothersome pain, JAK inhibitors are worth discussing. One registry analysis comparing TNF inhibitors to IL-6 receptor inhibitors in biologic-experienced patients found no significant differences in disease activity or patient-reported outcomes between those two biologic classes, suggesting that switching between biologics of similar type may not provide the same incremental pain benefit that a JAK inhibitor might.¹⁴

JAK inhibitors are not without downsides. Regulatory agencies have flagged elevated risks of blood clots, certain infections, and cardiovascular events in some patient populations, particularly in older adults with existing risk factors. Your rheumatologist will weigh these risks against the pain benefit.

Why Opioids Are Not the Answer

It is worth addressing opioids directly because they are prescribed to RA patients more often than the evidence supports. A Cochrane review found only limited evidence that weak opioids provide short-term pain relief in RA, and adverse effects were common enough to offset any benefit. There was not enough evidence to draw any conclusion about using opioids beyond six weeks, or about using strong opioids at all.¹⁵

Despite this, long-term opioid use is common in RA patients. A review of the literature found no studies demonstrating improved function or pain control with long-term opioid use in rheumatic diseases, but did find evidence of increased fracture risk and opioid poisoning hospitalizations. Perhaps most concerning, studies showed that patients on opioids tended to have delayed DMARD initiation and reduced DMARD use, raising the possibility that opioids mask symptoms of active disease and lead to worse outcomes by delaying proper treatment.¹⁶ Cohort data has confirmed that a high proportion of RA patients end up on opioids for more than 12 months, a duration at which dependence risk becomes a real concern.¹⁷ The consensus across the literature is that opioids do not have a routine role in chronic RA management.

When Pain Persists Despite Good Disease Control

Here is where the pain management picture gets genuinely complicated. Roughly a third of RA patients report significant, sometimes severe, widespread pain that is out of proportion to their measurable inflammation. This pain persists even when blood markers and joint swelling are well controlled. One study found that nearly half of RA patients showed evidence of central sensitization, a state in which the nervous system amplifies pain signals independent of what is happening in the joints. These patients had higher pain scores and more tender joints, but their inflammatory markers were similar to those without sensitization.¹⁸

This matters for medication choices because adding more anti-inflammatory drugs to treat pain that is not inflammatory in nature is ineffective and exposes you to side effects for no benefit. Research on early RA patients treated with methotrexate confirmed that a subgroup has pain that is not driven by inflammation, suggesting that alternative treatment strategies to traditional anti-inflammatory medications are needed.¹⁹ Recognizing this distinction can prevent overtreatment with immunosuppressive drugs and redirect attention toward approaches like certain antidepressants that modulate pain signaling (duloxetine is sometimes used in this context), physical therapy, exercise programs, and cognitive behavioral therapy. If you feel your pain is not matching your lab results, it is worth raising this specifically with your rheumatologist rather than assuming you need a stronger anti-inflammatory.

Cannabis and Other Complementary Approaches

Many people with RA turn to cannabis products for pain relief, and the science here is honest but unsatisfying. Cannabinoids do have anti-inflammatory and painkilling properties in preclinical models, and some animal studies have shown promising results. However, a scoping review of the evidence found that clinical studies in actual RA patients are scarce, and the data that does exist shows mixed results.²⁰ This does not mean cannabis cannot help an individual person feel better, but it does mean there is not enough evidence to recommend it as a reliable treatment. If you use it, treat it as a supplement to, not a replacement for, your DMARD therapy.

Topical treatments like diclofenac gel can provide localized relief with less systemic exposure than oral NSAIDs. These are most useful for accessible joints like hands and knees. Early-stage research into combination topical gels, such as capsaicin paired with diclofenac in nanoparticle formulations, suggests improved skin penetration and anti-inflammatory activity compared to conventional preparations, but this work remains in the lab for now.²¹

Pain Medications During Pregnancy and Breastfeeding

RA affects many women during their reproductive years, and managing pain during pregnancy requires a different medication map. Methotrexate and leflunomide are both teratogenic and must be stopped well before conception.²² NSAIDs should be avoided in the third trimester because they can affect fetal circulation and delay labor. Corticosteroids can be used throughout pregnancy at the lowest effective dose. For disease control, hydroxychloroquine, sulfasalazine, and azathioprine are considered safe options during pregnancy.

During breastfeeding, NSAIDs are generally passed into breast milk in low amounts. Shorter-acting options are preferred, with extra caution for premature infants. Prednisone is considered compatible with nursing, though at doses above 20 mg per day, waiting about four hours after a dose before feeding is recommended. Hydroxychloroquine and sulfasalazine are both compatible with breastfeeding.²³ Planning medication changes before conception, rather than scrambling to adjust once already pregnant, gives both you and your baby the safest start.

Can You Eventually Reduce Your Medications?

If your RA has been in stable remission for a sustained period, you may wonder whether you can taper or stop some medications. A phase 3 trial tested exactly this. Patients in stable remission were randomly assigned to continue full-dose treatment, taper to half dose, or taper and then stop entirely. About half of those who tapered maintained remission, though relapse rates were significantly higher than in those who stayed on full treatment. The reassuring finding was that most patients who did relapse regained remission after restarting their medications.²⁴ Tapering requires close monitoring with regular blood work and clinical assessments. It is not something to attempt on your own by quietly skipping doses, since uncontrolled flares can cause irreversible joint damage. But for people who have been in remission for a year or more, a carefully supervised dose reduction is a reasonable conversation to have with your rheumatologist, especially if you are concerned about long-term side effects of your current regimen.